Author

Sarah Jetzer

Institution: Molecular Partners (Switzerland)

Observed institutions: University of Zurich, Molecular Partners (Switzerland)

ORCID: 0000-0001-6178-6674

Observed ORCID: 0000-0001-6178-6674

OpenAlex ID: A5073264233

A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression

2022 · Nicolò Rigamonti, Niina Veitonmäki, et al. · Cancer Immunology Research · 32

Recommendations for Accurate Target Expression Evaluation by Quantitative Flow Cytometry

2025 · Tamara Lekishvili, Maxime Moulard, et al. · Cytometry Part A · 4

Abstract 1733: MP0317, a CD40xFAP targeting multi-specific DARPin® therapeutic, drives immune activation and reverts myeloid-mediated T-cell suppression in vitro and ex vivo

2021 · Kyriaki Ioannou, Simone Ragusa, et al. · Cancer Research · 3

MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation

2024 · Alexander Link, Teresa Maria Frasconi, et al. · Blood · 1

Non-canonical induction of autophagy increases adeno-associated virus type 2 (AAV2) transduction efficiency

2024 · Sereina O. Sutter, Sarah Jetzer, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1

Abstract 1073: A tumor-targeted CD40 agonistic DARPin® molecule leading to antitumor activity with limited systemic toxicity

2020 · Nicolo Rigamonti, Sarah Jetzer, et al. · Cancer Research · 1

1072 MP0632, a logic-gated conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors co-expressing MSLN and EpCAM

2026 · Stephan Wullschleger, Matteo Bianchi, et al. · Journal for ImmunoTherapy of Cancer

Abstract 1624: Logic-gated switch-DARPin T cell engager with CD2 co-stimulation for improved safety and efficacy in MSLN and EpCAM co-expressing ovarian cancer

2026 · Matteo Bianchi, Sarah Jetzer, et al. · Cancer Research

829 A next-generation conditional Switch-DARPin T cell engager with CD2 co-stimulation enabling selective activity against solid tumors which co-express mesothelin (MSLN) and EpCAM

2025 · Matteo Bianchi, Joanna Robinson, et al. · Journal for ImmunoTherapy of Cancer

Data from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression

2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.

Data from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression

2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.

Supplementary Figure from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression

2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.

Supplementary Figure from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression

2023 · Nicolò Rigamonti, Niina Veitonmäki, et al.

Works count: 13

Citation count: 42

H-index: 3

I10-index: 1